Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:November 19, 2013Completed
Hide Studies Not Open or Pending
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:November 19, 2013Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:January 22, 2016Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:September 21, 2010Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:May 11, 2011Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:February 10, 2017Terminated
Condition(s):DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell MyelomaLast Updated:May 23, 2023Active, not recruiting
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:September 23, 2013Completed
Condition(s):Multiple Myeloma and Plasma Cell Neoplasm; Renal FailureLast Updated:August 26, 2013Completed
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:April 2, 2020Completed
Condition(s):Multiple Myeloma; Plasma Cell NeoplasmLast Updated:May 18, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.